{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:19:28Z","timestamp":1764685168703,"version":"3.46.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.7759\/cureus.98307","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:16:52Z","timestamp":1764685012000},"source":"Crossref","is-referenced-by-count":0,"title":["Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report"],"prefix":"10.7759","author":[{"given":"Ibrahim","family":"Korucu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuba","family":"Karakoyun Alpay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20149","article-title":"Prevalence of progressive supranuclear palsy in Yonago, Japan","volume":"19","author":"Kawashima M","year":"2004","unstructured":"Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord. 2004, 19:1239-40. 10.1002\/mds.20149","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2019.10.013","article-title":"Progressive supranuclear palsy","volume":"149","author":"Giagkou N","year":"2019","unstructured":"Giagkou N, H\u00f6glinger GU, Stamelou M. Progressive supranuclear palsy. Int Rev Neurobiol. 2019, 149:49-86. 10.1016\/bs.irn.2019.10.013","journal-title":"Int Rev Neurobiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.557","article-title":"Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade","volume":"6","author":"Takigawa H","year":"2016","unstructured":"Takigawa H, Kitayama M, Wada-Isoe K, Kowa H, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav. 2016, 6:e00557. 10.1002\/brb3.557","journal-title":"Brain Behav"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1665-7","article-title":"Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series","volume":"133","author":"Yoshida K","year":"2017","unstructured":"Yoshida K, Hata Y, Kinoshita K, Takashima S, Tanaka K, Nishida N. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series. Acta Neuropathol. 2017, 133:809-23. 10.1007\/s00401-016-1665-7","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002794","article-title":"Progressive supranuclear palsy: diagnosis and management","volume":"21","author":"Rowe JB","year":"2021","unstructured":"Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021, 21:376-83. 10.1136\/practneurol-2020-002794","journal-title":"Pract Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318292a2d2","article-title":"The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy","volume":"80","author":"Massey LA","year":"2013","unstructured":"Massey LA, J\u00e4ger HR, Paviour DC, et al.. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013, 80:1856-61. 10.1212\/WNL.0b013e318292a2d2","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01692-6","article-title":"Midbrain\/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy","volume":"20","author":"Cui SS","year":"2020","unstructured":"Cui SS, Ling HW, Du JJ, et al.. Midbrain\/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy. BMC Neurol. 2020, 20:114. 10.1186\/s12883-020-01692-6","journal-title":"BMC Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0551-3","article-title":"Therapeutic management of the overlapping syndromes of atypical parkinsonism","volume":"32","author":"Giagkou N","year":"2018","unstructured":"Giagkou N, Stamelou M. Therapeutic management of the overlapping syndromes of atypical parkinsonism. CNS Drugs. 2018, 32:827-37. 10.1007\/s40263-018-0551-3","journal-title":"CNS Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2014.09.012","article-title":"Atypical parkinsonism: diagnosis and treatment","volume":"33","author":"Stamelou M","year":"2015","unstructured":"Stamelou M, Bhatia KP. Atypical parkinsonism: diagnosis and treatment. Neurol Clin. 2015, 33:39-56. 10.1016\/j.ncl.2014.09.012","journal-title":"Neurol Clin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams DR","year":"2005","unstructured":"Williams DR, de Silva R, Paviour DC, et al.. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005, 128:1247-58. 10.1093\/brain\/awh488","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0303-8467(02)00128-2","article-title":"Levodopa-induced oromandibular dystonia in progressive supranuclear palsy","volume":"105","author":"Tan EK","year":"2003","unstructured":"Tan EK, Chan LL, Wong MC. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg. 2003, 105:132-4. 10.1016\/s0303-8467(02)00128-2","journal-title":"Clin Neurol Neurosurg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20545","article-title":"Treatment of progressive supranuclear palsy and corticobasal degeneration","volume":"20 Suppl 12","author":"Lang AE","year":"2005","unstructured":"Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord. 2005, 20 Suppl 12:S83-91. 10.1002\/mds.20545","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10459","article-title":"Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders","volume":"18","author":"Litvan I","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, et al.. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003, 18:467-86. 10.1002\/mds.10459","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive supranuclear palsy: Advances in diagnosis and management","volume":"73","author":"Coughlin DG","year":"2020","unstructured":"Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020, 73:105-16. 10.1016\/j.parkreldis.2020.04.014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006564.pub2","article-title":"Dopamine agonist therapy in early Parkinson's disease","volume":"16","author":"Stowe RL","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, et al.. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev. 2008, 16:CD006564. 10.1002\/14651858.CD006564.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350218","article-title":"Botulinum toxin-A improves the rigidity of progressive supranuclear palsy","volume":"35","author":"Polo KB","year":"1994","unstructured":"Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol. 1994, 35:237-9. 10.1002\/ana.410350218","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2016.106","article-title":"Percutaneous endoscopic gastrostomy tube insertion in neurodegenerative disease: a retrospective study and literature review","volume":"50","author":"Sarkar P","year":"2017","unstructured":"Sarkar P, Cole A, Scolding NJ, Rice CM. Percutaneous endoscopic gastrostomy tube insertion in neurodegenerative disease: a retrospective study and literature review. Clin Endosc. 2017, 50:270-8. 10.5946\/ce.2016.106","journal-title":"Clin Endosc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial","volume":"23","author":"Stamelou M","year":"2008","unstructured":"Stamelou M, Reuss A, Pilatus U, et al.. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008, 23:942-9. 10.1002\/mds.22023","journal-title":"Mov Disord"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.074070","article-title":"Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study","volume":"77","author":"Williams DR","year":"2006","unstructured":"Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry. 2006, 77:468-73. 10.1136\/jnnp.2005.074070","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.03.003","article-title":"Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study","volume":"74","author":"Painous C","year":"2020","unstructured":"Painous C, Mart\u00ed MJ, Simonet C, et al.. Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. Parkinsonism Relat Disord. 2020, 74:67-73. 10.1016\/j.parkreldis.2020.03.003","journal-title":"Parkinsonism Relat Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.01.004","article-title":"Prediagnostic Progressive Supranuclear Palsy - Insights from the UK Biobank","volume":"95","author":"Street D","year":"2022","unstructured":"Street D, Whiteside D, Rittman T, Rowe JB. Prediagnostic Progressive Supranuclear Palsy - Insights from the UK Biobank. Parkinsonism Relat Disord. 2022, 95:59-64. 10.1016\/j.parkreldis.2022.01.004","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432024-richardson-syndrome-variant-of-progressive-supranuclear-palsy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:16:53Z","timestamp":1764685013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432024-richardson-syndrome-variant-of-progressive-supranuclear-palsy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.98307","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}